Psyence Biomedical (PBM) Other Non-Current Liabilities (2024 - 2025)
Psyence Biomedical's (PBM) quarterly Other Non-Current Liabilities came in at $298368.0 in Q3 2025, up 100.0% year-on-year from $149184.0 in Q3 2024, and up 49.11% quarter-over-quarter from $200096.0 in Q1 2025.
Psyence Biomedical (PBM) Other Non-Current Liabilities (2024 - 2025) Analysis & Trends
Psyence Biomedical's Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $298368.0 for Q3 2025.
- On a quarterly basis, Other Non-Current Liabilities rose 100.0% year-over-year to $298368.0 in Q3 2025; TTM through Sep 2025 was $298368.0, a 100.0% increase from a year earlier, with the FY2025 full-year figure at $200096.0, down 77.81% from the prior year.
- Other Non-Current Liabilities grew to $298368.0 in Q3 2025 per PBM's latest filing, from $200096.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $901608.0 in Q1 2024 and bottomed at $149184.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Psyence Biomedical | 1.56 Mn | 1.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 298,368.00 |
| Mar 31, 2025 | 200,096.00 |
| Sep 30, 2024 | 149,184.00 |
| Mar 31, 2024 | 901,608.00 |